Cancer Treatment Today

FERRIPROX® (deferiprone) is an oral medication designed to chelate, or remove,  iron overload from transfusions due to thalassemia syndromes when other chelation therapy, most commonly Exjade,  does not work. The studies for approval were done for teh situation when teh initial chaltion did not work (second line) because Ferroprox may be inferior to Exjade in first line. This is not an innocuous drug; the most serious side effect seen in about

FERRIPROX® (deferiprone) is an iron chelator indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. The approval in second line is reasonable both because the studies for approval were done in second line and because Ferroprox may be inferior to Exjade in first line (Cemak et al). This is not an innocuous drug; the most serious side effect seen in about